A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.

In addition, mice treated with 42105-74bbz CAR-T cells had a median survival of 56 days (n = 10, 50% survived at end-point) compared to 50 days for those treated with 19bbz CAR-T cells (n = 10, 20% survived at end-point); however the survival advantage did not reach statistical significance ( p = 0.0675) despite the fact that mice treated with 42105-74bbz CAR-T cells had the lowest number of MCL cells in both peripheral blood and spleen (Fig. 6 B).

also in 111,027 other papers